Company overview
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Daily valuation snapshot
These values are from the stored daily market snapshot dated 2026-10-08. They are not a live quote.
| Daily close (USD) | $2.7 |
| Market capitalization (USD) | $280,483,929.9 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.2 |
No matching rows. Clear the filter to see all records.
Continue the research
Read public ownership disclosures separately from company fundamentals. Test a strategy against dated historical observations before evaluating its assumptions; a past result is not a live trading outcome.